 | It is estimated that approximately 4.5 million people in the developed word are living with an abdominal aortic aneurysm and each year 600,000 new cases are diagnosed. Patients typically have no symptoms and, when they are diagnosed, they often undergo complex open surgical repair. Stent-graft therapy provides a minimally-invasive alternative, with reduced recovery times and potentially improved survival rates. |
|
 | An estimated 35,000 thoracic aortic surgical and endovascular interventions are performed every year in the developed world (10,000 in the US alone) at a combined cost to individuals, insurance companies and tax payers of $3.5 billion a year. |
|
 | The market for Fem-Pop Angioplasty & Stenting has experienced explosive growth recently mainly due to the launch and acceptance of novel atherectomy devices like the SilverHawk, and the regulatory approval of dedicated Stents.At the end of 2005 the market was estimated at $470 million, growing by 30% over the previous year. |
|
 | The market for Neuro-Endovascular Devices which currently stands at $590 million is expected to reach $1.1 billion by 2012. The increase in use of non-invasive neuro-imaging modalities in the outpatient setting has led to a sharp increase in the number of truly asymptomatic, intracranial aneurysms being diagnosed. Continuous improvement in coil design and composition, the introduction of stents for the management of wide-necked cerebral aneurysms and the advancement in guiding catheters and wire designs are improving the utility of coils in intracranial aneurysm repair. |
|
 | Latest research findings indicate that drug eluting stents (DES) reduce the need for re-intervention after PTCA to a greater extent than bare metal stents (BMS). The market for drug eluting stents has shown explosive growth since its inception and in 2004 it reached an estimated $4.2 billion in revenue worldwide. |
|
